vs

Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

Astera Labs, Inc. is the larger business by last-quarter revenue ($270.6M vs $197.9M, roughly 1.4× REPLIGEN CORP). Astera Labs, Inc. runs the higher net margin — 16.6% vs 6.7%, a 9.9% gap on every dollar of revenue. On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (91.8% vs 13.6%). Astera Labs, Inc. produced more free cash flow last quarter ($76.6M vs $17.6M). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (103.6% CAGR vs 14.4%).

Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

ALAB vs RGEN — Head-to-Head

Bigger by revenue
ALAB
ALAB
1.4× larger
ALAB
$270.6M
$197.9M
RGEN
Growing faster (revenue YoY)
ALAB
ALAB
+78.1% gap
ALAB
91.8%
13.6%
RGEN
Higher net margin
ALAB
ALAB
9.9% more per $
ALAB
16.6%
6.7%
RGEN
More free cash flow
ALAB
ALAB
$59.0M more FCF
ALAB
$76.6M
$17.6M
RGEN
Faster 2-yr revenue CAGR
ALAB
ALAB
Annualised
ALAB
103.6%
14.4%
RGEN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALAB
ALAB
RGEN
RGEN
Revenue
$270.6M
$197.9M
Net Profit
$45.0M
$13.3M
Gross Margin
75.6%
52.5%
Operating Margin
24.7%
9.0%
Net Margin
16.6%
6.7%
Revenue YoY
91.8%
13.6%
Net Profit YoY
82.0%
143.9%
EPS (diluted)
$0.25
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALAB
ALAB
RGEN
RGEN
Q4 25
$270.6M
$197.9M
Q3 25
$230.6M
$188.8M
Q2 25
$191.9M
$182.4M
Q1 25
$159.4M
$169.2M
Q4 24
$141.1M
$174.1M
Q3 24
$113.1M
$154.9M
Q2 24
$76.8M
$154.1M
Q1 24
$65.3M
$151.3M
Net Profit
ALAB
ALAB
RGEN
RGEN
Q4 25
$45.0M
$13.3M
Q3 25
$91.1M
$14.9M
Q2 25
$51.2M
$14.9M
Q1 25
$31.8M
$5.8M
Q4 24
$24.7M
$-30.3M
Q3 24
$-7.6M
$-654.0K
Q2 24
$-7.5M
$3.3M
Q1 24
$-93.0M
$2.1M
Gross Margin
ALAB
ALAB
RGEN
RGEN
Q4 25
75.6%
52.5%
Q3 25
76.2%
53.2%
Q2 25
75.8%
50.0%
Q1 25
74.9%
53.6%
Q4 24
74.0%
26.1%
Q3 24
77.7%
50.0%
Q2 24
77.9%
49.8%
Q1 24
77.4%
49.5%
Operating Margin
ALAB
ALAB
RGEN
RGEN
Q4 25
24.7%
9.0%
Q3 25
24.0%
8.9%
Q2 25
20.7%
7.6%
Q1 25
7.1%
3.9%
Q4 24
0.1%
-17.7%
Q3 24
-7.9%
-5.1%
Q2 24
-31.7%
1.0%
Q1 24
-127.1%
1.3%
Net Margin
ALAB
ALAB
RGEN
RGEN
Q4 25
16.6%
6.7%
Q3 25
39.5%
7.9%
Q2 25
26.7%
8.2%
Q1 25
20.0%
3.4%
Q4 24
17.5%
-17.4%
Q3 24
-6.7%
-0.4%
Q2 24
-9.8%
2.2%
Q1 24
-142.5%
1.4%
EPS (diluted)
ALAB
ALAB
RGEN
RGEN
Q4 25
$0.25
$0.24
Q3 25
$0.50
$0.26
Q2 25
$0.29
$0.26
Q1 25
$0.18
$0.10
Q4 24
$1.23
$-0.55
Q3 24
$-0.05
$-0.01
Q2 24
$-0.05
$0.06
Q1 24
$-1.77
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALAB
ALAB
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$167.6M
$767.6M
Total DebtLower is stronger
$542.2M
Stockholders' EquityBook value
$1.4B
$2.1B
Total Assets
$1.5B
$2.9B
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALAB
ALAB
RGEN
RGEN
Q4 25
$167.6M
$767.6M
Q3 25
$140.4M
$748.7M
Q2 25
$162.3M
$708.9M
Q1 25
$86.4M
$697.2M
Q4 24
$79.6M
$757.4M
Q3 24
$126.1M
$784.0M
Q2 24
$421.1M
$809.1M
Q1 24
$696.1M
$780.6M
Total Debt
ALAB
ALAB
RGEN
RGEN
Q4 25
$542.2M
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$525.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ALAB
ALAB
RGEN
RGEN
Q4 25
$1.4B
$2.1B
Q3 25
$1.3B
$2.1B
Q2 25
$1.1B
$2.1B
Q1 25
$1.0B
$2.0B
Q4 24
$964.8M
$2.0B
Q3 24
$889.6M
$2.0B
Q2 24
$845.3M
$2.0B
Q1 24
$808.8M
$2.0B
Total Assets
ALAB
ALAB
RGEN
RGEN
Q4 25
$1.5B
$2.9B
Q3 25
$1.4B
$2.9B
Q2 25
$1.3B
$2.9B
Q1 25
$1.1B
$2.9B
Q4 24
$1.1B
$2.8B
Q3 24
$983.1M
$2.8B
Q2 24
$915.5M
$2.9B
Q1 24
$864.9M
$2.8B
Debt / Equity
ALAB
ALAB
RGEN
RGEN
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALAB
ALAB
RGEN
RGEN
Operating Cash FlowLast quarter
$95.3M
$25.7M
Free Cash FlowOCF − Capex
$76.6M
$17.6M
FCF MarginFCF / Revenue
28.3%
8.9%
Capex IntensityCapex / Revenue
6.9%
4.1%
Cash ConversionOCF / Net Profit
2.12×
1.93×
TTM Free Cash FlowTrailing 4 quarters
$281.8M
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALAB
ALAB
RGEN
RGEN
Q4 25
$95.3M
$25.7M
Q3 25
$78.2M
$48.1M
Q2 25
$135.4M
$28.6M
Q1 25
$10.5M
$15.0M
Q4 24
$39.7M
$39.2M
Q3 24
$63.5M
$49.3M
Q2 24
$29.8M
$42.2M
Q1 24
$3.7M
$44.7M
Free Cash Flow
ALAB
ALAB
RGEN
RGEN
Q4 25
$76.6M
$17.6M
Q3 25
$65.9M
$43.4M
Q2 25
$133.3M
$21.5M
Q1 25
$6.0M
$11.4M
Q4 24
$24.3M
$33.6M
Q3 24
$46.8M
$42.3M
Q2 24
$28.5M
$37.4M
Q1 24
$228.0K
$36.4M
FCF Margin
ALAB
ALAB
RGEN
RGEN
Q4 25
28.3%
8.9%
Q3 25
28.6%
23.0%
Q2 25
69.5%
11.8%
Q1 25
3.7%
6.8%
Q4 24
17.2%
19.3%
Q3 24
41.4%
27.3%
Q2 24
37.1%
24.3%
Q1 24
0.3%
24.0%
Capex Intensity
ALAB
ALAB
RGEN
RGEN
Q4 25
6.9%
4.1%
Q3 25
5.3%
2.5%
Q2 25
1.1%
3.9%
Q1 25
2.8%
2.1%
Q4 24
10.9%
3.2%
Q3 24
14.8%
4.5%
Q2 24
1.7%
3.1%
Q1 24
5.2%
5.5%
Cash Conversion
ALAB
ALAB
RGEN
RGEN
Q4 25
2.12×
1.93×
Q3 25
0.86×
3.23×
Q2 25
2.64×
1.92×
Q1 25
0.33×
2.57×
Q4 24
1.61×
Q3 24
Q2 24
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons